Vascular Solutions (Nasdaq: VASC) is expected to report Q3 earnings on Oct. 18. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Vascular Solutions's revenues will grow 2.0% and EPS will grow 50.0%.

The average estimate for revenue is $24.8 million. On the bottom line, the average EPS estimate is $0.15.

Revenue details
 Last quarter, Vascular Solutions reported revenue of $24.7 million. GAAP reported sales were 11% higher than the prior-year quarter's $22.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.15. GAAP EPS of $0.15 for Q2 were 15% higher than the prior-year quarter's $0.13 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 66.7%, 70 basis points better than the prior-year quarter. Operating margin was 15.9%, 70 basis points better than the prior-year quarter. Net margin was 9.6%, 10 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $99.0 million. The average EPS estimate is $0.58.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 91 members out of 103 rating the stock outperform, and 12 members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give Vascular Solutions a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is buy, with an average price target of $14.30.